Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Royalty Pharma plc
  6. Summary
    RPRX   GB00BMVP7Y09

ROYALTY PHARMA PLC

(RPRX)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
38.90 USD   +0.49%
01/18More Drama For Combination SPCs
AQ
01/18Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
GL
01/09Transcript : Royalty Pharma plc Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 08:15 AM
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/23/2023 01/24/2023 01/25/2023 01/26/2023 01/27/2023 Date
38.35(c) 38.26(c) 38.72(c) 38.71(c) 38.9(c) Last
1 351 805 2 060 779 1 184 319 1 432 882 1 016 225 Volume
+0.05% -0.23% +1.20% -0.03% +0.49% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2 847 M - -
Net income 2022 569 M - -
Net Debt 2022 5 815 M - -
P/E ratio 2022 28,4x
Yield 2022 2,10%
Sales 2023 2 681 M - -
Net income 2023 1 003 M - -
Net Debt 2023 6 334 M - -
P/E ratio 2023 17,6x
Yield 2023 2,23%
Capitalization 17 159 M 17 159 M -
EV / Sales 2022 8,07x
EV / Sales 2023 8,76x
Nbr of Employees -
Free-Float 54,5%
More Financials
Company
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio... 
Read more
Sector
Pharmaceuticals
Calendar
02/15Earnings Release
More about the company
Ratings of Royalty Pharma plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ROYALTY PHARMA PLC
01/18More Drama For Combination SPCs
AQ
01/18Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On Febru..
GL
01/09Transcript : Royalty Pharma plc Presents at 41st Annual J.P. Morgan Healthcar..
CI
01/09Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J..
GL
01/09Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J..
AQ
01/09Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further..
GL
01/09Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further..
GL
01/09Ionis and Royalty Pharma Enter into Royalty Agreement for Up to $1.1 Billion to Further..
CI
01/09Royalty Pharma Announces Dividend Increase
GL
01/09Royalty Pharma Announces Dividend Increase
GL
01/09Royalty Pharma Declares First Quarter 2023 Dividend, Payable on March 15, 2023
CI
01/05Morphosys: 2023 only best-case growth for cancer drug Monjuvi
DP
01/04Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
GL
01/04Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
AQ
2022Arrowhead Pharmaceuticals Receives $25 Million Milestone Payment from Amgen for Olpasir..
MT
More news
News in other languages on ROYALTY PHARMA PLC
01/09Ionis et Royalty Pharma concluent un accord de redevances pouvant atteindre 1,1 milliar..
01/09Royalty Pharma déclare le dividende du premier trimestre 2023, payable le 15 mars 2023
01/05Morphosys: 2023 nur im besten Fall Wachstum beim Krebsmittel Monjuvi
2022Arrowhead Pharmaceuticals reçoit un paiement d'étape de 25 millions de dollars d'Amgen ..
2022Royalty Pharma annonce l'expansion de son équipe de direction supérieure
More news
Analyst Recommendations on ROYALTY PHARMA PLC
More recommendations
ETFs positioned on ROYALTY PHARMA PLCETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
AGFiQ US Market Neutral Anti-Beta Fund - USD19.07%-2.37%United_States
Renaissance IPO ETF - USD3.61%7.17%-United_States
SPDR S&P Pharmaceuticals ETF - USD3.39%1.59%United_States
VictoryShares Nasdaq Next 50 ETF - USD2.06%3.55%-NC
IShares Nasdaq US Biotechnology - USD1.82%1.78%United_States
More ETFs positioned on ROYALTY PHARMA PLC
Analysis
Roche's Alzheimer's drug fails to meet goal in long awaited trial
Chart ROYALTY PHARMA PLC
Duration : Period :
Royalty Pharma plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYALTY PHARMA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 38,90 $
Average target price 53,38 $
Spread / Average Target 37,2%
EPS Revisions
Managers and Directors
Pablo Gerardo Legorreta Chairman & Chief Executive Officer
Terrance Patrick Coyne Chief Financial Officer & Executive Vice President
James F. Reddoch Chief Scientific Officer & Executive VP
Marshall Urist Executive Vice President-Research & Investments
Sara Klymkowsky Senior Vice President-Research & Investments
Sector and Competitors
1st jan.Capi. (M$)
ROYALTY PHARMA PLC-1.57%17 159
JOHNSON & JOHNSON-4.77%439 835
ELI LILLY AND COMPANY-6.49%325 056
NOVO NORDISK A/S1.06%312 363
ROCHE HOLDING AG-0.40%277 685
MERCK & CO., INC.-5.02%267 180